allmu2018년 10월 23일 화요일 팜뉴스





English News

allmu2018년 10월 23일 화요일


pharm news

English News
HOME > 영문뉴스

Hanmi Pharm. to co-work with Lilly

‘HM71224’ for Lupus and proliferative arthritis

Leslie Chang ( 다른기사보기 

2015-03-19 오전 11:26 페이스북 트윗터 목록 보기 프린트

Hanmi Pharm. has announced on 19th of March that they had an agreement with Eli Lilly to co-work to develop BTK HM71224 and its license required.

This agreement is heading to pass the approval of US fair trading law, known as Hart-Scott-Rodino Antritrust Improvement Acts when they try to get more than certain range of intellectual property transferring.

The new drug is about to step into the phase-II clinical trial. Hanmi and Lilly are planning to work together to develop HM71224 on disease like proliferative arthritis, lupus, nephritis and sjogren's syndrome.

Thomas Bumol, EVP of R&D Lilly has stressed "there are still out numbers of patients out there under agony of immunization disease even though many remedies are available, therefore Lilly is trying their best to fulfill the market requirements and the patients needs in various ways"

He also said "Lilly is doing own research all alone as well. This agreement will enhance our portfolio in the field of immunization disease. We will certainly focus on the improvements the immunization field through HM71224 case".

Mr. Kwan-Soon Lee, President of Hanmi Pharm. said "Hanmi has confirmed the new viable way over HM71224 to cure the many immunization area like proliferative arthritis through the first phase of clinical trial in Europe. We are excited to work together with Lilly on this area and also would expect to provide the curable remedy throughout the cooperation with Lilly".
- Copyrights ⓒ PHARMNEWS, 무단 전재 및 재배포 금지 -

전체댓글 0

People & News